AmgenvsPrime Medicine

AMGN and PRME stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

PRME

Prime Medicine, Inc.

$3.55

Value $641M

-7.55%
PRME's page

Amgen (AMGN) has a market value of $235B and Prime Medicine (PRME) $641M. Over the last year, with dividends, AMGN moved +31.5% and PRME -4.6%. Dividend yield: AMGN 2.31%, PRME none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    PRME$641M

    AMGN is 366 times PRME

  • Revenue, 12 months

    AMGN$38.9B

    PRME$7.1M

    AMGN is 5,510 times PRME

  • Net income, 12 months

    AMGN$9.4B

    PRME-$176M

  • Operating margin

    AMGN32.4%

    PRME-2,584.2%

    2,616.6 points apart

  • ROIC

    AMGN16.2%

    PRME-176.8%

    193.0 points apart

  • P/E

    AMGN25.0

    PRME–

  • Dividend yield

    AMGN2.3%

    PRME0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+79.2%

PRME-48.9%

50100150200202420252026
Returns by period
PeriodAMGNWith dividendsPRMEWith dividends
1 year since November 19, 2025+31.5%Price +27.2%-4.6%Price -4.6%
3 years since November 20, 2023+79.2%+21.5% a yearPrice +64.2%-48.9%-20.1% a yearPrice -48.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenPRMEPrime Medicine

Valuation

AMGNPRME
Valuation
Price$435.64$3.55
Market value$235B$641M
Enterprise value (EV)$276B$580M
P/E25.0–
P/E, 5-year median23.0–
P/B16.476.0
EV/EBIT21.9–
Free cash flow yield4.1%–

Results and growth

AMGNPRME
Results and growth
Revenue, 12 months$38.9B$7.1M
Net income, 12 months$9.4B-$176M
Free cash flow, 12 months$9.6B-$159M
Earnings per share, 12 months$17.25-$0.98
Revenue growth, year on year10.0%55.3%
Revenue growth a year, past+7.6%over 5 years-2.3%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNPRME
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%-2,584.2%
Net margin24.1%-2,497.6%
ROIC16.2%-176.8%
ROE87.8%-216.3%

Balance sheet

AMGNPRME
Balance sheet
Cash$13.2B$61M
Total debt$54.0B$110M
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNPRME
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$10.08–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or PRME

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Prime Medicine?

By market value, Amgen ($235B) is about 366.4 times Prime Medicine ($641M), at today's prices.

How did AMGN and PRME stock do over the last 3 years?

Since November 20, 2023, AMGN's price moved +64.2% and PRME's -48.9%. With dividends: AMGN +79.2% (+21.5% a year), PRME -48.9% (-20.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or PRME?

The dividend yield at today's price is 2.31% for Amgen and none for Prime Medicine. Over the last twelve months they paid $10.08 and – per share.

Which has the higher profit margins, Amgen or Prime Medicine?

Over the last twelve months, the net margin was 24.1% for Amgen and -2,497.6% for Prime Medicine, and the operating margin 32.4% and -2,584.2%. Revenue was $38.9B and $7.1M.

Which is the better investment, Amgen or Prime Medicine?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.